Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Nat Nanotechnol. 2012 Apr 8;7(6):383–388. doi: 10.1038/nnano.2012.45

Figure 5. Improvement of cytotoxic nanomedicine effectiveness by vascular normalization.

Figure 5

a, Volumes of orthotopic E0771 mammary tumours in response to treatment with DC101 or non-specific rat IgG control (5mg/kg on days 0 and 3) in combination with either the ~10nm nanomedicine Abraxane (10mg/kg on days 1–5) or the ~100nm nanomedicine Doxil (2mg/kg on days 1–5). b, Quantification of tumour growth rates, based on the time to reach double the initial volume. Abraxane (P = 0.040, Mann-Whitney U-test) and Doxil (P = 0.040, Mann-Whitney U-test) monotherapy both induce growth delays versus the control treatment. Normalization with DC101 enhances the effectiveness of the ~10nm Abraxane (P = 0.040, Mann-Whitney U-test), but does not affect that of the ~100nm Doxil. Animal number n = 4–5 for all groups.

HHS Vulnerability Disclosure